Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
This report summarises results from an analysis conducted by ECDC and Eurofound to understand the impact of selected NPIs introduced from 2020 to 2022 in response to the COVID-19 pandemic on the WLB among EU adults.
Antiviral drugs and monoclonal antibodies (mAbs), administered either separately or as combination therapy 'cocktails’, have provided a valuable tool for fighting COVID-19. Surveillance data, coupled with data on antiviral treatment susceptibility, can guide clinical decisions on selecting the best therapy for the patient.
The aim of the study protocol is to measure product-specific COVID-19 vaccine effectiveness to prevent transmission of SARS-CoV-2 infection from healthcare workers to their contacts, which can be either other patients or healthcare workers, in healthcare settings.
In 2020, the European Commission stressed the importance of continuously monitoring the safety and effectiveness of vaccines in the EU/EEA during the post-authorisation phase, with particular emphasis on COVID-19 vaccines in the context of the ongoing pandemic.